NEW YORK (GenomeWeb News) – MDxHealth today reported a roughly 53 percent increase in its first-quarter revenues year over year driven by sales of its prostate cancer molecular test.

The Liege, Belgium-based firm said that total revenues for the three months ended March 31 were €1.1 million ($1.4 million), up from €719,000 for the first quarter of 2012. All of its revenues were derived from commercial product and service sales. The first quarter of last year included €137,000 in grant revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.